MedTrace Logo

A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients

NCT03600363 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2020-03-11

No results posted yet for this study

Summary

The study is to evaluate the therapeutic effect of metformin as a maintenance therapy in high risk patients with complete remission of diffuse large B lymphoma / stage III follicular lymphoma after chemotherapy in the initial R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus the monoclonal antibody rituximab) regimen

Conditions

  • Lymphoma, Large B-Cell, Diffuse
  • Stage III Follicular Lymphoma

Interventions

DRUG

Metformin

metformin (1.0g, bid) as a maintenance therapy in patients with complete remission

DRUG

Placebos

oral placebos as a maintenance therapy

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2021-01-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03600363 on ClinicalTrials.gov